22 results about "Upper urinary tract infection" patented technology

This utility model relates to the field of urine collection bag technology and discloses a urine collection bag for bladder irrigation in urological patients. It includes a lifting arm and a urine collection bag. A hook is fixedly connected to the middle of the upper surface of the lifting arm, and a warning light is installed in the middle of one side of the lifting arm. A power supply is installed inside the lifting arm. Slides are formed on both sides of the lifting arm. A conductive block is fixedly connected to one side of the bottom wall of the slide, and a spring is fixedly connected to the other side of the bottom wall of the slide. An inlet pipe is fixedly connected to one side of the upper surface of the urine collection bag, and a drain pipe is fixedly connected to the middle of the lower surface of the urine collection bag. This urine collection bag for bladder irrigation, through the design of an observation window and built-in scale lines, reduces the interference of bag deformation and light refraction on readings. Nursing staff can intuitively and accurately read the volume of irrigation waste fluid, ensuring accurate recording of intake and output balance, and providing reliable data support for assessing the patient's bladder irrigation effect, bleeding, and renal function recovery.

This application provides a method and system for predicting urinary tract infections related to urodynamic examinations. It addresses the limitations of current preventative measures, where methods with high evidence levels and good efficacy, including antibiotic intravesical instillation and weekly oral cyclic antibiotic therapy, inevitably require antibiotic use. The method includes: acquiring urodynamic examination data from a target patient; analyzing the curve information in the urodynamic examination data to obtain a curve numerical sequence corresponding to a time axis; extracting a urodynamic feature set based on the curve numerical sequence; constructing a medical history feature set based on the target patient's medical history data; inputting the urodynamic feature set and the medical history feature set into a urinary tract infection risk prediction model to output a risk prediction result for urinary tract infection after urodynamic examination. The risk prediction result includes at least a risk score or risk stratification result.

The application provides a catheterization device with an adjusting function, comprising: a catheter, one end of the catheter is provided with a catheter head for guiding urine into the catheter head, and the other end of the catheter is provided with an adjusting switch body for adjusting the rate and on-off of the urine discharged from the other end of the catheter; a balloon, the balloon is arranged on the outer peripheral wall of the catheter close to the catheter head, and the balloon can be filled with a medium to fix the catheter in the bladder of a human patient; two electrodes with opposite polarities, one end of each of the two electrodes penetrates through the catheter and extends into the catheter head along the length direction of the catheter, and the two electrodes are respectively used for connecting the positive electrode and the negative electrode of an electrophysiological monitoring device at the end outside the catheter; wherein the catheter, the catheter head and the balloon are all made of an electrically charged silicone rubber material. The application accelerates the recovery of the self-urination ability of the patient and reduces the risk of urinary tract infection of the patient through the adjustment of the adjusting switch body and the electrodes.

Disclosed are instillable compositions in the form of aqueous solutions comprising hyaluronic acid or a salt thereof and a complex of diclofenac or a salt thereof with 2-hydroxypropyl-beta- cyclodextrin and use thereof in the prevention of urinary tract infections.

Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

present invention discloses a urinary catheter system (100) comprising a catheter tube (111) with a rounded or oval catheter tip (101), a catheter stem (104) with thin-walled construction and wide internal lumen, drainage eyes / opening (102) positioned very low near the bladder neck, and securing means (103) configured to retain the catheter within a patient's urinary tract. The securing means (103) may comprise internal retention means like disc-shaped retention balloons, external fixation elements including adhesive pads (203, 302), or external collection elements including condom-type configurations (401). The drainage eyes (102) have rounded or oval configuration with smooth margins that are wider towards the lumen to prevent encrustation and blockage. The system provides complete emptying of the bladder with minimal residual urine accumulation, thereby reducing complications associated with urinary tract infections. Ref. Figure 1

The present invention relates to compositions comprising an American cranberry extract combined with phospholipids, and the use thereof in the prevention and treatment of urinary tract infections. The invention also relates to processes for the preparation of said compositions, and formulations for oral administration comprising said compositions.

This invention relates to the field of traditional Chinese medicine technology, specifically to a granule for promoting urination and eliminating stones, its preparation method, and its application. The granule comprises the following ingredients: *Lysimachia christinae*, *Pyrrosia lingua*, *Cynanchum paniculatum*, talc, stir-fried chicken gizzard lining, *Polygonum aviculare*, *Dianthus superbus*, *Plantago asiatica*, *Tetrapanax papyriferus*, *Poria cocos*, *Coix lacryma-jobi*, *Paeonia lactiflora*, vinegar-processed *Corydalis yanhusuo*, *Astragalus membranaceus*, and *Achyranthes bidentata*. The entire formula integrates clearing heat and promoting urination, dissolving stones, tonifying qi and relieving pain, and guiding the medicine downwards. It primarily focuses on purging while supplementing with tonifying, achieving the combined effects of clearing heat and promoting diuresis, and dissolving stones. It is used for damp-heat accumulation, stone accumulation, or combined with deficiency of vital energy leading to urinary tract infections, stones, or hematuria. Symptoms include frequent urination, burning and stinging pain, yellow or reddish urine, abdominal cramps, difficulty urinating or stones in the urine, red tongue with yellow or greasy coating, and a slippery and rapid pulse. This composition has the effects of clearing heat and promoting diuresis, relieving strangury and expelling stones. It is used for heat strangury, stone strangury and hematuria caused by damp-heat accumulation, with symptoms such as frequent urination, burning and stinging pain, yellow or reddish urine or blood in urine, lower back and abdominal colic, difficulty in urination or gravel in urine, red tongue with yellow or yellow and greasy coating, and slippery and rapid pulse.

This invention belongs to the food or pharmaceutical field, specifically relating to a probiotic and prebiotic composition, its preparation process, and its application. The composition includes probiotics, resistant dextrin, xylooligosaccharides, fructooligosaccharides, stachyose, erythritol, and cranberry powder, prepared using a fluidized bed spray granulation process. As an adjuvant to antibiotics, this composition has been verified in animal and clinical trials to synergistically treat upper / lower respiratory tract infections and urinary tract infections, shorten symptom duration, accelerate recovery from the primary disease, maintain intestinal flora diversity, increase the abundance of beneficial bacteria such as Bifidobacteria, reduce the incidence of adverse reactions, and alleviate antibiotic-associated diarrhea. This invention provides a microecological restoration solution for antibiotic treatment, possessing clear clinical value and technological feasibility.

This invention provides a dual-segment, dual-color pH comparison catheter for clinical identification of premature rupture of membranes, belonging to the field of medical catheter technology. It includes a main catheter tube with a urine segment pH membrane and an amniotic fluid segment pH membrane sequentially arranged along the axial direction on the anterior outer wall of the main tube. The urine segment pH membrane has a color development range of pH 5.5-6.5, and its color change is a continuous gradient from yellow to green. This invention achieves zero-sampling detection under sterile conditions, highly integrating pH identification function into routine catheterization procedures. The pH value of urine and any potentially mixed amniotic fluid is simultaneously detected upon catheter insertion into the bladder, without the need for vaginal speculum, sampling swabs, or any form of secondary sterile opening. This design completely blocks the path of exogenous bacteria into the maternal reproductive tract at a physical level, thereby fundamentally and effectively reducing the incidence of clinically common chorioamnionitis and urinary tract infections, and improving perinatal medical safety and quality.

To overcome the problems of poor lubrication and easy transport of exogenous contaminants during ureteral stent placement in the human body, the present invention provides a ureteral stent and its preparation method. The ureteral stent includes a stent body and a lubricating and antibacterial coating. The lubricating and antibacterial coating includes a hydrophilic copolymer, an antibacterial agent, and a catalyst. The hydrophilic copolymer includes component A and component B. Component A includes a cross-linked ionic liquid of a high molecular weight polymer, and component B includes a 2-(dimethylamino)methacrylate-maleate-acrylamide copolymer. The ureteral stent provided by the present invention can play a good lubricating role, reducing the frictional resistance of the stent body. The polymerization reaction of component A and component B forms a hydrophilic copolymer with a gel network structure. This hydrophilic copolymer is cross-linked with the antibacterial agent to form a lubricating and antibacterial coating with an antibacterial gel network structure. The formed lubricating and antibacterial coating has good deformation resistance and mechanical properties, and can prevent the adhesion of impurities such as cell clusters, anion and cation clusters, and bacteria / fungi to the ureteral stent, avoiding urinary tract infections caused by stent placement.

This invention discloses a method and apparatus for predicting the risk of urinary tract infection (UTI) in children with urinary tract stones based on nomograms. The method includes: acquiring and preprocessing clinical data of pediatric patients to obtain a raw dataset; performing univariate analysis on the training set based on clinical indicators to obtain candidate variables significantly associated with UTI; performing multivariate logistic regression analysis on the candidate variables to obtain independent predictors; constructing a nomogram model based on the independent predictors; calculating a corresponding score for each independent predictor in the nomogram model; calculating the total score of the independent predictors and obtaining the prediction probability; and performing quantitative evaluation and curve analysis on the prediction probabilities to obtain the UTI risk assessment results. This invention is the first to organically integrate four indicators: gender, mean CT value, U-LEU, and NIT, greatly improving the efficiency of clinical decision-making.

The present application provides a kind of polypeptide sustained-release hydrogel coating for preventing catheter urinary tract infection and its preparation method, the coating includes the adhesive bottom layer attached to the surface of catheter substrate, and the polypeptide sustained-release hydrogel functional layer compounded outside the adhesive bottom layer;The functional layer includes hydrophilic hydrogel gel-forming matrix, targeted antibacterial polypeptide, polypeptide sustained-release carrier and biocompatible auxiliary agent.The present application solves the interface bonding problem of hydrophobic catheter substrate and hydrophilic hydrogel through the adhesive bottom layer, the coating has strong adhesion, is resistant to urine immersion and rubbing;Through polypeptide sustained-release carrier, antibacterial polypeptide is released for 30 days, and there is no risk of burst release;The targeted antibacterial polypeptide used is specific to urinary tract infection pathogenic bacteria, has no drug resistance induction risk, has excellent biocompatibility, can effectively prevent catheter-related urinary tract infection caused by short-term and long-term indwelling catheter, the preparation process is simple and controllable, is suitable for large-scale production, and can be widely applied to antibacterial modification of urinary intervention medical devices.

A pistoning prevention system (PPS) that will improve catheter associated urinary tract infection rates of an indwelling Foley catheter while maintaining reliability, comfort, & safety. With the PPS incorporated within a Foley catheter during manufacturing it will eliminate the excess stretch along a specific length of a Foley catheter that resides within the patient's urethra. The excessive amount and ease of stretch is responsible for the pistoning action of an indwelling Foley catheter moving in and out of the urethra. This action is responsible for the retrograde movement of bacteria outside the body & into the urethra, bladder, & kidneys increasing preventable infections. With much prevention work globally, the pistoning action of a Foley catheter is now known to be partially or wholly to blame for the attributed $340 million spent in the U.S. on healthcare costs & 13,000 associated deaths making this an immediate global patient safety emergency.

The invention relates to compositions comprising two or more ribonucleic acid (RNA) polynucleotides comprising an open reading frame (ORF) encoding at least one Eschericia coli (E. coli) fimbrial antigen polypeptide or an immunogenic fragment thereof, wherein the RNA polynucleotide encodes fimbrial antigen H (FimH) protein and / or PapG protein and is formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

The invention relates to compositions comprising two or more ribonucleic acid (RNA) polynucleotides comprising an open reading frame (ORF) encoding at least one Eschericia coli (E.coli) fimbrial antigen polypeptide or an immunogenic fragment thereof, wherein the RNA polynucleotide encodes fimbrial antigen H (FimH) protein and / or PapG protein and is formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

This invention relates to the field of pharmaceutical synthesis technology, specifically disclosing a 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative and its general structural formula; it also discloses the preparation method and application of this derivative. This 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative exhibits good inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and can be used to prevent and treat diseases caused by MRSA infection. Preferably, these diseases include, but are not limited to, pneumonia, urinary tract infections, bacteremia, sepsis, and suppurative arthritis caused by MRSA in humans and animals. The beneficial effects of this invention are: the 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative of this invention is obtained through a four-step reaction, the preparation method is simple, and the reaction conditions are mild; it has good inhibitory and bactericidal activity against MRSA and can be used to prevent and treat diseases caused by MRSA infection.

Disclosed herein includes a nanoplasmonic sensor for molecular characterization of urinary tract infections. In some embodiments, the nanoplasmonic sensor can also be used at the point-of-care. The nanoplasmonic sensor utilizes an optical phenomenon that occurs between a metal nanoparticle and a dielectric – localized surface plasmon resonance (LSPR) – for the detection of bacterial nucleic acids. In some embodiments, the spectral peak shift is a function of target sequence concentration.

A method for preventing and treating internal infections, e.g., urinary tract infections, caused by catheters is provided, in particular by reduction in catheter-associated biofilms. A coating composition is used to treat the catheter and applied through the catheter into the bladder or other body urinary tract organ to kill or neutralize microorganisms, including biofilms therein. The composition comprises a humectant and an antimicrobial with the antimicrobial including a monoquaternary ammonium compound or pharmaceutically acceptable salt thereof. The coating layer has antimicrobial cidal or static activity for at least about one hour.

The present disclosure provides for a vaccine comprising an Acinetobacter adhesin protein or fragment thereof and a pharmaceutically acceptable carrier or adjuvant. The vaccine may be used for treating or preventing a urinary tract infection (UTI) in a subject in need thereof, particularly a catheter-associated UTI (CAUTI). In some embodiments, the Acinetobacter adhesin protein or fragment thereof is an isolated Acinetobacter chaperone-usher pathway (CUP) adhesin protein or immunogenic fragment thereof.

The utility model relates to the technical field of medical appliances, disclose a valve formula anti -reflux antibacterial urinary catheter, design includes catheter, one -way valve subassembly and connector subassembly, the catheter body includes the pipe body and the pipe head, one -way valve subassembly includes first valve and second valve, the first valve is fixed in the pipe head and is equipped with, the first valve is used for one -way control to pipe head position, the pipe body is away from the pipe head one end fixed connection has connector subassembly, second valve is located in connector subassembly, second valve is used for one -way control to the pipe body is away from pipe head one end, through catheter, one -way valve subassembly and connector subassembly cooperation can effectively prevent urine reflux, thereby effectively prevent the patient from using catheter and cause urinary tract infection, reduce the use risk of catheter.

This utility model relates to a urinary catheterization device for obstetric and gynecological care, aiming to solve the technical problem that although current methods can effectively prevent urine remaining inside the catheter from dripping directly into the external environment, the dripped urine left in the sealed box is prone to bacterial growth, odor, and urinary tract infection. The device includes a urine belt and a catheter. The top of the urine belt is connected to a connecting tube, and the bottom of the catheter is connected to a spherical balloon. The bottom of the spherical balloon is connected to a soft catheter. Both the catheter and the soft catheter have check valves on their outer sides. The bottom of the soft catheter is connected to a rigid connecting tube, and the connecting tube is sleeved on the outside of the rigid connecting tube. This utility model prevents residual urine inside the catheter from dripping onto the catheter surface or into the sealed box, causing contamination, and can also unclog the catheter, ensuring normal urinary catheterization.